Radiofrequency ablation for Barrett esophagus with confirmed low-grade dysplasia

JAMA

Volumn 311, Issue 12, 2014, Pages 1205-1206

  Mönkemüller, Klaus ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER MORTALITY; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DYSPLASIA; EDITORIAL; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; HUMAN; MORBIDITY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT INDICATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CATHETER ABLATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84896603668     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.2512     Document Type: Editorial

References (15)

1. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149-1158.
2. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049-1057.
3. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2006;4(5):566-572.
4. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology. 2011;140(3):e18-e52.
5. Coco DP, Goldblum JR, Hornick JL, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol. 2011;35(1):45-54.
6. Downs-Kelly E, Mendelin JE, Bennett AE, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol. 2008;103(9):2333-2340.
7. Sikkema M, Looman CW, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106(7):1231-1238.
8. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523-1530.
9. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10):781-789.
10. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360(22):2277-2288.
11. Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013;145(1):96-104.
12. Phoa KN, van Vilsteren FGI, Weusten BLAM, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized trial. JAMA. doi:10.1001/jama.2014.2511.
13. Mokrowiecka A,Wierzchniewska-Lawska A, Smolarz B, et al. Amplification of Her-2/neu oncogene in GERD - Barrett's metaplasia - dysplasia - adenocarcinoma sequence. Hepatogastroenterology. 2013;60(125):1063-1066.
14. Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology. 2012;143(4):927-935, e3.
15. Prasad GA,Wang KK, Halling KC, et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology. 2008;135(2):370-379.